Publications by authors named "Lindsey Buhring"
Article Synopsis
- The study aims to investigate the causes behind the thin phenotype in knockout (KO) mice lacking a specific orphan GPCR, linking this to improved glucose homeostasis.
- Male and female KO mice showed significantly lower body fat and energy intake compared to their wild type (WT) counterparts, while maintaining similar energy expenditure and activity levels.
- Findings indicate that KO mice have enhanced glucose tolerance and insulin sensitivity, suggesting potential benefits of inhibiting GPR75 in managing obesity and metabolic health in humans.
Article Synopsis
- Treatments that lower blood glucose and body weight are beneficial for type 2 diabetes patients; LX4211 is a new oral medication that inhibits SGLT1 and SGLT2 to improve glycemic control and promote weight loss.
- * In preclinical studies, LX4211 effectively blocked glucose transport in various animal models and significantly increased urinary glucose excretion for over 24 hours.
- * Long-term treatment with LX4211 improved glucose levels and insulin response in diabetic mice, but some weight loss effects were countered by increased food intake in certain models, suggesting a complex relationship between the drug's effects and appetite.
Improved glycemic control in mice lacking Sglt1 and Sglt2.
Am J Physiol Endocrinol Metab
January 2013
Sodium-glucose cotransporter 2 (SGLT2) is the major, and SGLT1 the minor, transporter responsible for renal glucose reabsorption. Increasing urinary glucose excretion (UGE) by selectively inhibiting SGLT2 improves glycemic control in diabetic patients. We generated Sglt1 and Sglt2 knockout (KO) mice, Sglt1/Sglt2 double-KO (DKO) mice, and wild-type (WT) littermates to study their relative glycemic control and to determine contributions of SGLT1 and SGLT2 to UGE.
View Article and Find Full Text PDFThe prevalence of diabetes throughout the world continues to increase and has become a major health issue. Recently there have been several reports of inhibitors directed toward the sodium-dependent glucose cotransporter 2 (SGLT2) as a method of maintaining glucose homeostasis in diabetic patients. Herein we report the discovery of the novel O-xyloside 7c that inhibits SGLT2 in vitro and urinary glucose reabsorption in vivo.
View Article and Find Full Text PDF